Tiziana Life Sciences PLC(TLSA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TLSA Tiziana Life Sciences PLC

Post-Mkt 04-15 19:21:03 EDT

0.8100

+0.0099

+1.24%

盘后0.7901

-0.0199-2.46%

18:43 EDT

High0.8390	Low0.7860	Vol52.25K
Open0.7900	D1 Closing0.8001	Amplitude6.62%
Mkt Cap88.36M	Tradable Cap56.49M	Total Shares109.09M
T/O42.44K	T/O Rate0.07%	Tradable Shares69.74M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"TLSA","market":"US","secType":"STK","nameCN":"Tiziana Life Sciences PLC","latestPrice":0.81,"timestamp":1744747200000,"preClose":0.8001,"halted":0,"volume":52248,"hourTrading":{"tag":"盘后","latestPrice":0.7901,"preClose":0.81,"latestTime":"18:43 EDT","volume":253,"amount":204.03450650000002,"timestamp":1744756992227},"delay":0,"floatShares":69737013,"shares":109085902,"eps":-0.133432,"marketStatus":"Post-Mkt","change":0.0099,"latestTime":"04-15 19:21:03 EDT","open":0.79,"high":0.839,"low":0.786,"amount":42444.06301968,"amplitude":0.066242,"askPrice":0.85,"askSize":3000,"bidPrice":0.7901,"bidSize":11,"shortable":3,"etf":0,"ttmEps":-0.133432,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1744761600000},"marketStatusCode":4,"adr":0,"adrRate":2,"listingDate":1542690000000,"exchange":"NASDAQ","adjPreClose":0.8001,"postHourTrading":{"tag":"盘后","latestPrice":0.7901,"preClose":0.81,"latestTime":"18:43 EDT","volume":253,"amount":204.03450650000002,"timestamp":1744756992227},"volumeRatio":0.180594,"impliedVol":0.6839,"impliedVolPercentile":0.7052},"requestUrl":"/m/hq/s/TLSA","defaultTab":"news","newsList":[{"id":"2524674954","title":"BRIEF-Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab In Phase 2 Multiple Sclerosis Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2524674954","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524674954?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 20:08","pubTimestamp":1743595731,"startTime":"0","endTime":"0","summary":"BRIEF-Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab In Phase 2 Multiple Sclerosis Clinical TrialApril 2 (Reuters) - Tiziana Life Sciences Ltd TLSA.O:TIZIANA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nTUA9CQQQR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2524462721","title":"Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2524462721","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524462721?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 20:00","pubTimestamp":1743595201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nTUA9CQQQR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2522884724","title":"Tiziana Life Sciences files $250M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2522884724","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522884724?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 03:17","pubTimestamp":1742930242,"startTime":"0","endTime":"0","summary":"17:22 EDT Tiziana Life Sciences (TLSA) files $250M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-mov...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tiziana-life-sciences-files-250m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tiziana-life-sciences-files-250m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2522881855","title":"Tiziana Life Sciences announces dosing of new patients at Yale MS Center","url":"https://stock-news.laohu8.com/highlight/detail?id=2522881855","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522881855?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 02:40","pubTimestamp":1742928041,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences (TLSA) announced dosing of new patients at Yale MS Center which is participating in our multicenter Phase 2 clinical trial ev...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tiziana-life-sciences-announces-dosing-of-new-patients-at-yale-ms-center?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tiziana-life-sciences-announces-dosing-of-new-patients-at-yale-ms-center?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","BK4585","LU1668664300.SGD","LU2028103732.USD","TLSA","LU0158827948.USD","LU2111349929.HKD","LU0912757837.SGD","LU2133065610.SGD","LU1162221912.USD","LU0106831901.USD","LU2271345857.HKD","LU0267386448.USD","IE00BZ1G4Q59.USD","BK4139","LU0795875086.SGD","BK4581","LU2089283258.USD","LU0106261372.USD","LU0795875169.SGD","LU0971096721.USD","LU1989772923.USD","BK4504","IE00BKVL7J92.USD","LU0314104364.USD","LU1732800096.USD","BK4127","LU2347655156.SGD","LU0158827781.USD","LU0006306889.USD","LU1720051108.HKD","LU0320765646.SGD","LU1989772840.SGD","LU1732799900.SGD","LU2357305700.SGD","LU1548497426.USD","LU1074936037.SGD","LU1363072403.SGD","LU2089284900.SGD","BK4516","LU0225283273.USD","LU2023251221.USD","LU1720051017.SGD","LU0098860793.USD","BK4588"],"gpt_icon":0},{"id":"2522002409","title":"Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2522002409","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522002409?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:00","pubTimestamp":1742904002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nTUAYRBSV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TLSA"],"gpt_icon":0},{"id":"2522795016","title":"Stocks to Watch Tuesday: Trump Media, Tesla, Samsung, GameStop -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2522795016","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522795016?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 17:05","pubTimestamp":1742893500,"startTime":"0","endTime":"0","summary":"Trump Media : Shares in the operator of Truth Social, majority owned by President Trump, jumped almost 10% in premarket trading after it signed an agreement with Crypto.com to launch exchange-traded funds and products.Samsung Electronics : The head of Samsung's smartphone and consumer-electronics business died from cardiac arrest Tuesday, jolting the company during a business slide that leaders have called a crisis. Samsung shares fell over 1% in Seoul.Boeing : Boeing is seeking to withdraw an earlier agreement to plead guilty in a long-running criminal case that blamed the company for deceiving regulators before two deadly crashes, The Wall Street Journal reported. Boeing shares edged down premarket.GameStop  is due to report results after markets close, while earnings from Smithfield Foods  and McCormick  are scheduled this morning.This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL .","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4516","LU2326559502.SGD","GB00B4LPDJ14.GBP","LU0820561818.USD","SFD","TSYW.SI","LU0689472784.USD","LU2404859741.USD","LU2360107168.USD","LU0348723411.USD","LU1674673691.USD","LU1066053197.SGD","IE00BWXC8680.SGD","LU2750360997.AUD","BK4604","SG9999015978.USD","LU2471134523.USD","LU2360106780.USD","MKC","LU0198837287.USD","LU0234572021.USD","BK4574","LU0690374615.EUR","TSLL","LU1914381329.SGD","BK4577","LU2756315318.SGD","TRUMP.USD.CC","BK4212","LU2471134879.HKD","BK4548","LU1778281490.HKD","GB00B4QBRK32.GBP","LU1839511570.USD","DJT","BK4550","BK4564","LU1861220033.SGD","TLSA","SG9999015952.SGD","LU0466842654.USD","BK4581","BK4547","SG9999015945.SGD","LU0077335932.USD","BK4598","LU1861559042.SGD"],"gpt_icon":1},{"id":"2522083708","title":"BRIEF-Tiziana Life Sciences Ltd Files For Mixed Shelf Of Up To $250 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522083708","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522083708?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 05:22","pubTimestamp":1742851333,"startTime":"0","endTime":"0","summary":"BRIEF-Tiziana Life Sciences Ltd Files For Mixed Shelf Of Up To $250 Million - SEC FilingMarch 24  - Tiziana Life Sciences Ltd TLSA.O:TIZIANA LIFE SCIENCES LTD FILES FOR MIXED SHELF OF UP TO $250 MILLION - SEC FILINGSource text: [ID:n0001013762-25-001691]Further company coverage: TLSA.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q70X2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2522837760","title":"Tiziana Life Sciences Ltd Files for Mixed Shelf of up to $250 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522837760","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522837760?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 05:21","pubTimestamp":1742851314,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q70X2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TLSA"],"gpt_icon":0},{"id":"2520540842","title":"Tiziana Life Sciences to Present at the 37th Annual Roth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2520540842","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520540842?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 20:00","pubTimestamp":1742212800,"startTime":"0","endTime":"0","summary":"NEW YORK, March 17, 2025  -- Tiziana Life Sciences, Ltd.  , a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the CEO of Tiziana Life Sciences, Ivor Elrifi, will be presenting during a fireside chat at the 37th Annual ROTH Conference and host 1x1 investor meetings. The Conference is being held March 16-18, 2025, in Dana Point, California. This year’s event will consist of 1-on-1 / small group meetings, analyst-selected fireside chats, industry keynotes and panels with executive management attending from approximately 450 private and public companies in a variety of growth sectors.Presentation Details:Date: Tuesday, March 18, 2025Time of Presentation: 12:00 pm PST / 15:00 pm ET / 19:00 pm GMTFormat: Virtual Fireside Chat1x1 Meetings: Please contact your ROTH representative.Tiziana Life Sciences is a clinical-stage biopharmaceutical company","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tiziana-life-sciences-present-37th-120000583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU1585245621.USD","LU2506951875.HKD","EA","BK4577","LU0823417737.USD","LU2506952170.USD","LU2506951958.HKD","BK4533","BK4585","LU1430594728.SGD","BK4085","LU2506952097.USD","BK4532","LU2247934214.USD","TLSA","LU0006061336.USD","LU0823417653.USD","BK4588","LU0950375773.USD"],"gpt_icon":0},{"id":"2519807603","title":"Tiziana Life Sciences Regains Compliance With Nasdaq Listing Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2519807603","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519807603?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 21:51","pubTimestamp":1741960285,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences (TLSA) said Friday it has regained compliance with Nasdaq's minimum bid price requirement.Tiziana fulfilled the requirement of maintaining a minimum closing bid price of $1.00 or","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2210149790.SGD","BK4585",".IXIC","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","NDAQ","IE00B64PRP62.GBP","TLSA","BK4112","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4588","BK4139","NQmain"],"gpt_icon":0},{"id":"2519805774","title":"Tiziana Life Sciences Regains Compliance With Nasdaq Listing Minimum Bid Price Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2519805774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519805774?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 20:30","pubTimestamp":1741955401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nTUA277BY3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2519864857","title":"Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2519864857","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519864857?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 01:05","pubTimestamp":1741885520,"startTime":"0","endTime":"0","summary":"As the United States stock market grapples with volatility, driven by concerns about economic health and shifting investor sentiment, opportunities in lesser-known areas like penny stocks are gaining attention. While the term 'penny stocks' might seem outdated, these investments often represent smaller or newer companies that can offer growth potential at lower price points. When backed by strong financials and sound fundamentals, they provide investors a chance to uncover hidden value amidst broader market fluctuations.Overview: Oramed Pharmaceuticals Inc. focuses on the research and development of pharmaceutical solutions for diabetes treatment and orally ingestible capsules for polypeptide delivery, with a market cap of $105.62 million.Overview: Tiziana Life Sciences Ltd is a biotechnology company that develops molecules for treating oncology and immunology diseases in the United States, with a market cap of $149.45 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oramed-pharmaceuticals-2-other-penny-170520527.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PHX","BK4179","BK4007","TTI","AVIR","SB","BABB","BK4213","BK4021","TLSA","BK4563","ORMP","BK4209"],"gpt_icon":0},{"id":"2516671713","title":"Tiziana Life Sciences Files New Drug Application for ALS Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2516671713","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516671713?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 22:02","pubTimestamp":1741096975,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences  said Tuesday it filed an investigational new drug application for foralumab, a potential treatment for amyotrophic lateral sclerosis, with the US Food and Drug Administration.The application is supported by a grant from the ALS Association as part of the Hoffman ALS Clinical Trial Awards Program, the company said.The company's development programs for Foralumab, a nasal anti-CD3 monoclonal antibody, are also being focused on multiple sclerosis and Alzheimer's disease.Upon getting the agency's clearance, Tiziana said it plans to begin a 20-patient clinical trial of two doses of intranasal foralumab aimed at evaluating the safety and early-stage parameters of disease improvement in amyotrophic lateral sclerosis.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","TLSA"],"gpt_icon":0},{"id":"2516476676","title":"BRIEF-Tiziana Life Sciences Files Investigational New Drug Application With FDA For ALS Phase 2 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2516476676","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516476676?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 21:22","pubTimestamp":1741094568,"startTime":"0","endTime":"0","summary":"BRIEF-Tiziana Life Sciences Files Investigational New Drug Application With FDA For ALS Phase 2 Clinical TrialMarch 4 (Reuters) - Tiziana Life Sciences Ltd TLSA.O:TIZIANA LIFE SCIENCES FILES INVESTIGA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA6Q4YSZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TLSA"],"gpt_icon":0},{"id":"2516679316","title":"Tiziana Life Sciences files IND application with FDA for ALS Phase 2 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2516679316","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516679316?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 21:16","pubTimestamp":1741094187,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences (TLSA) announced the submission of its Investigational New Drug, IND, application to the U.S. Food and Drug Administration, F...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tiziana-life-sciences-files-ind-application-with-fda-for-als-phase-2-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tiziana-life-sciences-files-ind-application-with-fda-for-als-phase-2-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLSA"],"gpt_icon":0},{"id":"2516117675","title":"Tiziana Life Sciences Files Investigational New Drug Application With FDA for ALS Phase 2 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2516117675","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516117675?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 21:00","pubTimestamp":1741093205,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA6Q4YSZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TLSA"],"gpt_icon":0},{"id":"2516510357","title":"Why Tiziana Life Sciences Ltd (TLSA) is Skyrocketing So Far in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516510357","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516510357?lang=en_us&edition=full_marsco","pubTime":"2025-03-02 22:25","pubTimestamp":1740925556,"startTime":"0","endTime":"0","summary":"We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025.In this article, we are going to take a look at where Tiziana Life Sciences Ltd  stands against the other biotech stocks.No matter the market environment, you’ll always find entertainment in the biotech space. There will always be biotech stocks making huge swings in both directions and these stocks can make or break your portfolio in a very small amount of time due to the nature of how important clinical trial results are for these companies.The United Nations forecasts that the over-65 age group will grow by 150% from 800 million in 2024 to 2 billion by 2067. This \"older, richer & sicker\" population is expected to push global healthcare spending on medicines up 12% to $2.3 trillion by 2028. If you combine that with AI making breakthroughs in healthcare more frequent, you’ll see many more biotech stocks starting to pop to the upside over the coming years.Tiziana Life Sciences Ltd  is up","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-tiziana-life-sciences-ltd-142556400.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TLSA","NQmain","QID","PSQ",".IXIC","SQQQ","TQQQ","MNQmain","USAW.SI","TSYW.SI","USJW.SI","QLD","BK4139","NVIW.SI"],"gpt_icon":1},{"id":"2514024388","title":"Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury","url":"https://stock-news.laohu8.com/highlight/detail?id=2514024388","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514024388?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 21:00","pubTimestamp":1740661200,"startTime":"0","endTime":"0","summary":"Traumatic brain injury is a leading cause of death and disability. Currently, there is no treatment to prevent the long-term effects of traumatic brain injury. “This study highlights the critical role of immune modulation in improving recovery time and outcomes after traumatic brain injury,” said Dr. Saef Izzy, lead author and neurologist at Brigham and Women’s Hospital. “We found that nasal anti-CD3 therapy effectively harnesses the body’s own immune system to counteract the damaging effects of neuroinflammation while enhancing the brain’s reparative mechanisms. These findings offer exciting potential for developing a much-needed therapeutic approach for TBI patients.”“The positive results from this study provide strong support for advancing nasal anti-CD3  as a novel and promising treatment for traumatic brain injury,” said Dr. Howard L. Weiner, Co-Director of the Ann Romney Center for Neurologic Diseases at BWH. “By modulating the immune system through simple nasal delivery, we are ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tiziana-life-sciences-announces-groundbreaking-130000643.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TLSA"],"gpt_icon":0},{"id":"2514099335","title":"Tiziana : Nasal Anti-Cd3 (Foralumab) Preclinical Study Nearing Completion, Foralumab Could Offer Treatment for Long Covid","url":"https://stock-news.laohu8.com/highlight/detail?id=2514099335","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514099335?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 21:08","pubTimestamp":1740488903,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG0G3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2514338099","title":"Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2514338099","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514338099?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 21:00","pubTimestamp":1740488400,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb. 25, 2025  -- Tiziana Life Sciences, Ltd.  , a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a nasal anti-CD3  preclinical study is nearing completion, and that foralumab could offer a novel and effective treatment for long COVID. This innovative approach works by reducing microglial activation, a key factor in the persistent brain inflammation associated with long COVID, thereby addressing the debilitating neurological and psychiatric symptoms many patients face.Previously, Tiziana conducted a human clinical study in patients with mild to moderate COVID-19 where foralumab was nasally administered once a day for 10 consecutive days. Treatment was well-tolerated and produced significant reduction in lung inflammation as assessed by computerized tomography  scanning. The aim of the human study was to assess safety of intrana","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tiziana-life-sciences-announces-long-130000505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0950375773.USD","LU1668664300.SGD","LU0225283273.USD","LU2347655156.SGD","LU0106831901.USD","LU2133065610.SGD","LU0795875086.SGD","LU1989772923.USD","LU0795875169.SGD","BK4127","BK4585","LU2111349929.HKD","TLSA","BK4581","LU1074936037.SGD","LU0158827781.USD","LU0267386448.USD","LU0320765646.SGD","LU0158827948.USD","LU2089283258.USD","LU2506952170.USD","LU0823417653.USD","LU1162221912.USD","LU2247934214.USD","CNS","LU1732800096.USD","LU1430594728.SGD","LU1585245621.USD","BK4533","BK4534","LU2089284900.SGD","LU2506952097.USD","LU2357305700.SGD","LU0106261372.USD","LU0098860793.USD","LU1720051017.SGD","LU2506951875.HKD","BK4085","LU1363072403.SGD","LU0314104364.USD","IE00BZ1G4Q59.USD","BK4532","EA","LU1720051108.HKD","LU2506951958.HKD","LU1989772840.SGD","LU0823417737.USD","BK4504","LU2023251221.USD","LU0006306889.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tizianalifesciences.com","stockEarnings":[{"period":"1week","weight":-0.1112},{"period":"1month","weight":-0.4904},{"period":"3month","weight":0.1036},{"period":"6month","weight":-0.0908},{"period":"1year","weight":0.8184},{"period":"ytd","weight":0.1492}],"compareEarnings":[{"period":"1week","weight":0.0689},{"period":"1month","weight":-0.0421},{"period":"3month","weight":-0.074},{"period":"6month","weight":-0.0742},{"period":"1year","weight":0.0553},{"period":"ytd","weight":-0.0801}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-  receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":0.069015},{"month":2,"riseRate":0.142857,"avgChangeRate":0.005731},{"month":3,"riseRate":0.428571,"avgChangeRate":0.177199},{"month":4,"riseRate":0.428571,"avgChangeRate":0.077398},{"month":5,"riseRate":0.5,"avgChangeRate":0.232591},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.027358},{"month":7,"riseRate":0.333333,"avgChangeRate":0.284279},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.121008},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.050999},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.071181},{"month":11,"riseRate":0,"avgChangeRate":-0.138622},{"month":12,"riseRate":0,"avgChangeRate":-0.127005}],"exchange":"NASDAQ","name":"Tiziana Life Sciences PLC","nameEN":"Tiziana Life Sciences PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.1","shortVersion":"4.33.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tiziana Life Sciences PLC(TLSA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tiziana Life Sciences PLC(TLSA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tiziana Life Sciences PLC,TLSA,Tiziana Life Sciences PLC股票,Tiziana Life Sciences PLC股票老虎,Tiziana Life Sciences PLC股票老虎国际,Tiziana Life Sciences PLC行情,Tiziana Life Sciences PLC股票行情,Tiziana Life Sciences PLC股价,Tiziana Life Sciences PLC股市,Tiziana Life Sciences PLC股票价格,Tiziana Life Sciences PLC股票交易,Tiziana Life Sciences PLC股票购买,Tiziana Life Sciences PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tiziana Life Sciences PLC(TLSA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tiziana Life Sciences PLC(TLSA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction